Experimental flu vaccine enters human testing

NCT ID NCT06863142

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests an experimental flu vaccine called FluMos-v2, with or without an adjuvant (ALFQ), in 45 healthy adults aged 18-50. Participants receive two shots four months apart and are followed for 15 months. The goal is to check safety and how well the vaccine triggers an immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

FluMos-v2 vaccine with or without ALFQ adjuvant

What this could lead to

If successful, this could lead to a more effective flu vaccine that protects against multiple strains.

What could go wrong

This is an early Phase 1 trial with only 45 people, so safety and immune response are still being tested. The vaccine may not work as hoped.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA PREVENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

viral infectious disease influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••